Allarity (ALLR) Therapeutics announced the presentation of a poster containing data on a new DRP, Drug Response Predictor, for the monoclonal antibody drug daratumumab. The poster is to be presented during a session at the 2025 American Association for Cancer Research, AACR, Annual Meeting, taking place April 25-30, 2025, in Chicago, IL. This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab, “This is yet another successful application of our DRP technology beyond our internal clinical program pipeline,” said Thomas Jensen, CEO of Allarity Therapeutics. “We already offer an extensive portfolio of DRPs for research use, and the addition of a DRP for daratumumab-our first developed for an antibody therapy-further demonstrates the versatility and flexibility of our DRP platform. Until now, our DRPs have been developed exclusively for small-molecule drugs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity Therapeutics Restructures Board of Directors
- Biotech Alert: Searches spiking for these stocks today
- Allarity launches effort to combat potential illegal naked short selling
- Allarity announces presentation from Phase 2 trial with stenoparib monotherapy
- Allarity announces final settlement with SEC including $2.5M civil penalty